|
|
| Elekta Instruments, Inc. and 4-D Neuroimaging Announce a Strategic Agreement To Distribute MEG Systems in the U.S. |
SAN DIEGO, Feb. 19 /PRNewswire-FirstCall/ -- Elekta Instruments, Inc.
("Elekta") and 4-D Neuroimaging ("4-D") (OTC Bulletin Board: FDNX) today
joined forces to offer a complete non-invasive solution for a range of
neurosurgical procedures. Through the integration of non-invasive
neurological diagnosis of brain disease by magnetoencephalography (MEG) with
minimally invasive radiosurgical treatment by the Leksell Gamma Knife(R),
physicians and hospitals will now be able to offer diagnostic and treatment
pathways for a number of brain diseases that are less invasive, less costly
and more efficient than current approaches. The scope of the agreement
encompasses marketing, sales, support and development programs.
D. Scott Buchanan, Ph.D., 4-D's Chief Executive Officer commented, "This
agreement provides an avenue to expand our coverage of the neurological and
neurosurgical community at an opportune time following the recent announcement
of CPT codes for MEG. We feel that by working with Elekta's highly respected
marketing and sales organization, and bringing the value of MEG's non-invasive
approach to Elekta's installed base of customers, we will accelerate the
clinical use of MEG.
"MEG allows physicians to non-invasively identify and localize sources of
abnormal brain activity, such as epileptic foci, as well as essential eloquent
cortical areas within the brain. We believe that the combination of the 4-D
MEG and Leksell Gamma Knife offers unique possibilities to diagnose and treat
functional disorders in the brain such as epilepsy. The MEG will further
enhance the utilization of Leksell Gamma Knife including new indications.
This agreement is a milestone for non-invasive neurosurgery and provides a
natural extension to our very successful relationship in the distribution of
4-D MEG systems in Japan," stated Tomas Puusepp, President and CEO of Elekta
North and South America.
Elekta is the world's largest supplier of neurosurgical and radiosurgical
solutions and the 2nd largest supplier of radiation oncology. Elekta Precise
Solutions includes a comprehensive range of non-invasive cancer care and
minimally invasive neurosurgery systems including radiosurgery and stereotaxy,
backed by a global network of clinical, technical and financial support
services.
4-D Neuroimaging is dedicated to the development of MEG systems, which
measure magnetic fields in the human brain and body and assist in the
diagnosis of a potentially broad range of medical disorders. More than
250 insurance companies have approved reimbursement on a case-by-case basis
for certain MEG procedures performed with Magnes and Vectorview systems, and
the American Medical Association has approved the issuance of billing codes,
commonly referred to as Common Procedural Terminology (CPT) codes, for the use
of MEG, (also known as magnetic source imaging, MSI). Additional information
about 4-D and its products can be found on its web site:
http://www.4dneuroimaging.com .
This press release may contain forward-looking statements that involve
risks and uncertainties. Actual results may differ from what is expressed or
implied here. Risks and uncertainties that could cause or contribute to such
differences include, but are not limited to, 4-D's ability to continue to
operate as a going concern, market acceptance of new applications,
competition, obtaining routine reimbursements from third party payers,
regulatory approvals and other factors. These and other risks are described
in detail in 4-D's filings with the U.S. Securities and Exchange Commission.
4-D is not obligated to publicly update or revise these forward-looking
statements.
SOURCE 4-D Neuroimaging
back to topRelated links:
CONTACT:
D. Scott Buchanan, President & CEO of 4-D
Neuroimaging, +1-858-453-6300; or Lars Jonsteg, VP Corporate
Relations of Elekta AB, +46 8 587 254 82; or Tomas Puusepp,
President & CEO of Elekta North and South America,
+1-770-300-9725
